The development of biologic agents has significantly improved the care of patients with autoimmune and inflammatory disorders. However, emerging patient care data, especially on side effects, have muddled the clinical practice picture.
The Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology has a highly successful record of providing evidence-based continuing medical education activities to practitioners in rheumatology. The Centerâ€™s biannual Biologic Therapies Summits have been key venues for presenting comprehensive reviews and clinical analyses of biologic therapies.
The Biologic Therapies Summit IV continues that successful tradition, both in terms of quality presentations and in fulfilling attendeesâ€™ educational objectives. An international faculty of experts who span a multitude of scientific disciplines will provide their insights on a variety of timely topics:
- Research advances in immunodeficiencies and autoimmunity,
- Approved biologic agents and clinical data,
- New biologic agents being developed,
- Toxicities associated with biologic agents,
- Clinical implications and potential new indications.
Join the Cleveland Clinic Richard J. Fasenmyer Center for Clinical Immunology and the Cleveland Society of Rheumatology for these outstanding presentations on the clinical use of biologics to treat autoimmune and inflammatory disorders.
|The Summit is directed to:
As a result of attending this Summit, the participant will be able to do the following:
- Review and describe recent advances in basic immunology including B cell biology, cytokine biology, biology of the inflammasome, cell trafficking, and interferon biology;
- Describe the molecular basis of intracellular signaling pathways (eg, JAK-STAT and other kinase pathways) as they relate to immune physiology in health and disease;
- Critically appraise data from preclinical models of disease and human immunodeficiency states as they apply to predicting efficacy and toxicity of current and future biologic therapies;
- Discuss clinical implications of data on stem cell therapy of autoimmune and inflammatory disease states;
- Describe the mechanisms of action, indications, and toxicity of newly approved biologic agents, including both monoclonal proteins and small molecules, intravenous immunoglobulins, and stem cell therapy, as well as those in late development, and assess their clinical implications for rheumatology, gastroenterology, dermatology, and neurology;
- Summarize recent data on side effects associated with biologic therapies (including infection, cardiovascular disease, and rare adverse events) and apply the data to patient care decisions;
- Review data from early and advanced clinical trials of approved and developing biologic therapies in a variety of inflammatory and autoimmune disorders including rheumatoid arthritis, lupus, psoriatic arthritis, spondylitis, inflammatory bowel disease, psoriasis, scleroderma, osteoporosis, SjÃ¶grenâ€™s syndrome, vasculitis, autoinflammatory diseases, and gout;
- Create management strategies for highly complex patient scenarios with biologics and compare those management decisions with global experts.